Hello, Sign in
My Account
My Account
New customer? Start here
| Catalog # | Availability | Size | Quantity | Unit Price | Save For Later Wish List | |
|---|---|---|---|---|---|---|
| VAG0154-2 | 7 days | 2 µg | $120.00 |
Select product before adding to cart
|
||
| VAG0154-10 | 7 days | 10 µg | $400.00 | |||
| VAG0154-100 | 7 days | 100 µg | $2,880.00 |
Product Overview | |
| Name | H1N1 California |
|---|---|
| Description | |
| H1N1 Influenza Virus California/04/2009 Recombinant | |
| Introduction | |
| H1N1 is a subtype specie of Influenza A virus. H1N1 Influenza Virus has mutated into various strains such as the Spanish Flustrain, mild humanflu strains, endemic pigstrains, and various strains found in birds. The Influenza A Virus is a globular particle about 100nm in diameter, sheathed in a lipid bilayer derived from the plasma membrane of its host. Studded in the lipid bilayer are two integral membrane proteins some 500 molecules of hemagglutinin ("H") and some 100 molecules of neuraminidase ("N"). Within the lipid bilayer are 3000 molecules of matrix protein and 8 pieces of RNA. Each of the 8 RNA molecules is associated with many copies of a nucleoprotein, several molecules of the three subunits of its RNA polymerase some "non-structural" protein molecules of uncertain function. | |
| Physical Appearance | |
| Sterile Filtered colorless solution. | |
| Formulation | |
| The H1N1 A/New Caledonia/20/99 IVR solution contains STE, 0.09% sodium azide (NaN 3 ) and 0.005% thimerosal. | |
| Stability | |
| A/New Caledonia/20/99 IVR although stable 4°C for 4 weeks, should be stored below -18°C. Please prevent freeze-thaw cycles. | |
| Purity | |
| Greater than 90.0% as determined by ELISA analysis. | |
| References | |
| 1. Title: A Patented Strain of Bacillus coagulans Increased Immune Response to Viral Challenge . Publication : DOI : 10.3810/pgm.2009.03.1971 Postgraduate Medicine: Volume: 121 No.2 Link : H1N1 New Caledonia prospec publication 2. Title: Clonal dissection of the human memory B-cell repertoirefollowing infection and vaccination Publication: European journal of immunology 39.5 (2009): 1260-1270. Link: H1N1 Influenza-A Virus prospec publication | |
| Inactivation | |
| Thimerosal and beta propiolactone treatment This product has been treated in a manner consistent with methods of inactivation. Generally accepted good laboratory practices appropriate to microbiological/viral safe handling practices and techniques are required at work. | |
| Immunological Activity | |
| Tested with anti-influenza A monoclonal antibodies in ELISA.Serological studies of influenza A virus, immunogen for antibody production. | |
| Precautions | |
| H1N1 California is for research use only and not for use in diagnostic or therapeutic procedures. | |
References |
1. Title :Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. Publication : The Rockefeller University Press , doi: 10.1084/jem.20101352 © 2011 Wrammert et al. Link : H1N1 California prospec publication |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from ADMEbio to advance their research.
Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
Thank you,
ADMEbio Team
ADMEbio welcomes feedback from our customers.
Thank you,
ADMEbio Team
